Key Points
- Insider Jennifer Michaelson sold 995 shares of Cullinan Therapeutics on Dec. 15 at an average price of $11.90 for $11,840.50, reducing her stake by 0.72% to 136,878 shares (about $1.63M).
- She previously sold 2,148 shares on Dec. 12 at $12.38 and 4,000 shares on Nov. 24 at $12.30, indicating a string of recent insider dispositions.
- CGEM opened at $10.22, trades in a one‑year range of $5.68–$13.33, and has a consensus analyst rating of Moderate Buy with a consensus target price of $28.29.
Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) insider Jennifer Michaelson sold 995 shares of the business's stock in a transaction on Monday, December 15th. The stock was sold at an average price of $11.90, for a total value of $11,840.50. Following the completion of the transaction, the insider directly owned 136,878 shares of the company's stock, valued at approximately $1,628,848.20. The trade was a 0.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Jennifer Michaelson also recently made the following trade(s):
- On Friday, December 12th, Jennifer Michaelson sold 2,148 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $12.38, for a total value of $26,592.24.
- On Monday, November 24th, Jennifer Michaelson sold 4,000 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $12.30, for a total transaction of $49,200.00.
Cullinan Therapeutics Stock Performance
CGEM stock opened at $10.22 on Wednesday. Cullinan Therapeutics, Inc. has a one year low of $5.68 and a one year high of $13.33. The firm has a market cap of $603.80 million, a price-to-earnings ratio of -3.09 and a beta of -0.10. The firm has a 50-day simple moving average of $9.18 and a two-hundred day simple moving average of $8.09.
Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.95) by $0.18. As a group, equities analysts predict that Cullinan Therapeutics, Inc. will post -3.04 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on CGEM. HC Wainwright increased their price objective on Cullinan Therapeutics from $24.00 to $26.00 and gave the company a "buy" rating in a report on Thursday, November 20th. Zacks Research upgraded Cullinan Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Tuesday, September 16th. Wall Street Zen upgraded Cullinan Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, November 22nd. Wedbush upped their price objective on shares of Cullinan Therapeutics from $25.00 to $34.00 and gave the company an "outperform" rating in a report on Tuesday, December 9th. Finally, New Street Research set a $26.00 target price on shares of Cullinan Therapeutics in a research note on Thursday, November 20th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $28.29.
Read Our Latest Analysis on Cullinan Therapeutics
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the company. Lynx1 Capital Management LP lifted its stake in Cullinan Therapeutics by 31.0% during the 3rd quarter. Lynx1 Capital Management LP now owns 5,766,090 shares of the company's stock valued at $34,193,000 after acquiring an additional 1,365,248 shares during the period. Caption Management LLC raised its holdings in shares of Cullinan Therapeutics by 107.0% during the third quarter. Caption Management LLC now owns 28,389 shares of the company's stock worth $168,000 after purchasing an additional 435,062 shares during the last quarter. Nuveen LLC acquired a new position in Cullinan Therapeutics during the first quarter valued at $1,423,000. Algert Global LLC boosted its holdings in Cullinan Therapeutics by 411.5% in the first quarter. Algert Global LLC now owns 221,430 shares of the company's stock valued at $1,676,000 after purchasing an additional 178,138 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its position in Cullinan Therapeutics by 1,665.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 177,685 shares of the company's stock worth $1,054,000 after purchasing an additional 167,623 shares during the period. 86.31% of the stock is owned by institutional investors and hedge funds.
Cullinan Therapeutics Company Profile
(
Get Free Report)
Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
